Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

ABSTRACT:

Background

The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab are administered to colorectal cancer (CRC) patients who harbor wild-type RAS proto-oncogenes. However, a percentage of patients do not respond to this treatment. In addition to mutations in the RAS genes, mutations in other genes, such as BRAF, PI3KCA, or PTEN, could be involved in the resistance to anti-EGFR moAb therapy.

Methods

In order to develop a comprehensive approach for the detection of mutations and to eventually identify other genes responsible for resistance to anti-EGFR moAbs, we investigated a panel of 21 genes by parallel sequencing on the Ion Torrent Personal Genome Machine platform. We sequenced 65 CRCs that were treated with cetuximab or panit

SUBMITTER: Lupini L 

PROVIDER: S-EPMC4624582 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature